MedTrace Logo

Neurological Blood-based Biomarkers and Cognitive Disorders in Critically Ill Survivors.

NCT05953311 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-07-20

No results posted yet for this study

Summary

Cognitive disorders are common after intensive care. Currently, their diagnosis is based on clinical tests. The investigators plan to study the relationship between different neurological blood biomarkers (cytokines, S100β protein, neuron specific enolase, total Tau protein and neurofilament light chain) and the occurrence of cognitive disorders during the three months following intensive care discharge.

Conditions

  • Intensive Care Unit Syndrome
  • Post-intensive Care Syndrome
  • Cognitive Disorder

Interventions

OTHER

Blood analysis

Blood analysis for neurological biomarkers measurements

OTHER

Cognitive tests

Questionnaires assessing cognitive function

Sponsors & Collaborators

  • University of Liege

    lead OTHER

Principal Investigators

  • Anne-Françoise Rousseau, MD, PhD · University hospital of Liège

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-23
Primary Completion
2025-06-30
Completion
2025-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05953311 on ClinicalTrials.gov